Small molecule · developed by Fulcrum Therapeutics
Pociredir (FTX-6058) is an agent studied in healthy adult subjects and in patients with sickle cell disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07401823 | Phase 2 | Sickle Cell Disease | Terminated | FULC |
| NCT05169580 | Phase 1 | Sickle Cell Disease | Completed | FULC |
| NCT04586985 | Phase 1 | Healthy Adult Subjects | Completed | FULC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Adult SubjectsSickle Cell AnemiaSickle Cell Disease
Updated Nov 15, 2026. Something wrong or missing? Report it on the FULC page.
See FULC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FULC catalysts and pipeline →